27802446|t|Human Leucocyte Antigen B50 Is Associated with Conversion to Generalized Myasthenia Gravis in Patients with Pure Ocular Onset
27802446|a|The aim of this study was to investigate the associations between major histocompatibility complex (MHC) class I and II alleles and disease characteristics in Turkish patients with myasthenia gravis (MG). The MHC class I and II alleles of 108 unrelated MG patients were genotyped. The human leucocyte antigen (HLA) distribution of all MG patients and subgroups of MG patients (grouped according to disease characteristics) was compared to that of 250 healthy controls. Overall distributions of HLA-B*61 and C*05 were more frequent in MG patients (7.4 vs. 2.0% and 14.8 vs. 6.8%, respectively) than in non-MG patients. Subgroup analyses revealed that HLA-DRB1*14 and DQB1*02 alleles were more frequent in early-onset MG [n = 10 (20.8%) vs. n = 25 (10.0%) and n = 21 (43.8%) vs. n = 59 (23.6%)]. In patients seropositive for anti-AchR antibodies, the frequencies of HLA-B*50 and C*05 were higher. HLA-C*05, DRB1*01, and DRB1*11 were higher in patients with ocular MG. In addition, HLA-A*01, A*31, B*08, and DRB1*14 were higher among patients with thymic hyperplasia, whereas DQB1*03 was lower. However, all of these differences lost significance after correction of the p value for multiple comparisons. No allele association was found among patients with thymoma. Strikingly, patients with generalized MG who had pure ocular symptoms at disease onset had significantly increased HLA-B*50 compared to the controls (corrected p < 0.001, OR = 9.92; 95% CI 3.05-32.22). The HLA-B*50 allele was associated with conversion to generalized disease in patients with pure ocular symptoms at disease onset. This finding could extend our understanding of the complex interactions between the pathogenesis of MG and genetic heritage.
27802446	0	27	Human Leucocyte Antigen B50	T129	C0444008
27802446	31	41	Associated	T080	C0439849
27802446	47	57	Conversion	T169	C0439836
27802446	61	90	Generalized Myasthenia Gravis	T047	C0751339
27802446	94	102	Patients	T101	C0030705
27802446	108	119	Pure Ocular	T047	C0751340
27802446	120	125	Onset	T080	C0332162
27802446	130	133	aim	T078	C1947946
27802446	142	147	study	T062	C0008972
27802446	155	166	investigate	T169	C1292732
27802446	171	183	associations	T080	C0439849
27802446	192	224	major histocompatibility complex	T028	C0024518
27802446	226	229	MHC	T028	C0024518
27802446	231	238	class I	T028	C0017355
27802446	243	253	II alleles	T028	C0017349
27802446	258	281	disease characteristics	T046	C0599878
27802446	285	292	Turkish	T098	C0549217
27802446	293	301	patients	T101	C0030705
27802446	307	324	myasthenia gravis	T047	C0026896
27802446	326	328	MG	T047	C0026896
27802446	335	338	MHC	T028	C0024518
27802446	339	346	class I	T028	C0017355
27802446	351	361	II alleles	T028	C0017349
27802446	379	381	MG	T047	C0026896
27802446	382	390	patients	T101	C0030705
27802446	396	405	genotyped	T059	C1285573
27802446	411	434	human leucocyte antigen	T116,T129	C0019721
27802446	436	439	HLA	T116,T129	C0019721
27802446	461	463	MG	T047	C0026896
27802446	464	472	patients	T101	C0030705
27802446	477	486	subgroups	T185	C1515021
27802446	490	492	MG	T047	C0026896
27802446	493	501	patients	T101	C0030705
27802446	503	510	grouped	T082	C0439745
27802446	524	547	disease characteristics	T046	C0599878
27802446	553	561	compared	T052	C1707455
27802446	577	593	healthy controls	T080	C2986479
27802446	620	628	HLA-B*61	T116,T129	C0062847
27802446	633	637	C*05	T116,T129	C0062856
27802446	648	656	frequent	T079	C0332183
27802446	660	662	MG	T047	C0026896
27802446	663	671	patients	T101	C0030705
27802446	734	742	patients	T101	C0030705
27802446	744	752	Subgroup	T185	C1515021
27802446	753	761	analyses	T062	C0936012
27802446	776	787	HLA-DRB1*14	T028	C0002085
27802446	792	807	DQB1*02 alleles	T028	C0002085
27802446	818	826	frequent	T079	C0332183
27802446	830	841	early-onset	T033	C1833334
27802446	842	844	MG	T047	C0026896
27802446	923	931	patients	T101	C0030705
27802446	932	944	seropositive	T080	C0521143
27802446	949	969	anti-AchR antibodies	T116,T129	C0236516
27802446	975	986	frequencies	T079	C0439603
27802446	990	998	HLA-B*50	T116,T129	C0369392
27802446	1003	1007	C*05	T116,T129	C0062856
27802446	1013	1019	higher	T080	C0205250
27802446	1021	1029	HLA-C*05	T116,T129	C0062856
27802446	1031	1038	DRB1*01	T116,T129	C1566853
27802446	1044	1051	DRB1*11	T129	C1699878
27802446	1057	1063	higher	T080	C0205250
27802446	1067	1075	patients	T101	C0030705
27802446	1081	1090	ocular MG	T047	C0751340
27802446	1105	1113	HLA-A*01	T129	C0019728
27802446	1115	1119	A*31	T116,T129	C0121978
27802446	1121	1125	B*08	T116,T129	C0019737
27802446	1131	1138	DRB1*14	T116,T129	C0122040
27802446	1144	1150	higher	T080	C0205250
27802446	1157	1165	patients	T101	C0030705
27802446	1171	1189	thymic hyperplasia	T047	C0040115
27802446	1199	1206	DQB1*03	T116,T129	C0122020
27802446	1211	1216	lower	T080	C0205251
27802446	1257	1269	significance	T078	C0750502
27802446	1294	1301	p value	T081	C1709380
27802446	1306	1326	multiple comparisons	T081	C1881925
27802446	1331	1337	allele	T028	C0002085
27802446	1338	1349	association	T080	C0439849
27802446	1366	1374	patients	T101	C0030705
27802446	1380	1387	thymoma	T191	C0040100
27802446	1401	1409	patients	T101	C0030705
27802446	1415	1429	generalized MG	T047	C0751339
27802446	1438	1449	pure ocular	T047	C0751340
27802446	1450	1458	symptoms	T184	C1457887
27802446	1462	1475	disease onset	T079	C0277793
27802446	1480	1493	significantly	T078	C0750502
27802446	1494	1503	increased	T081	C0205217
27802446	1504	1512	HLA-B*50	T116,T129	C0369392
27802446	1529	1537	controls	T080	C2986479
27802446	1549	1550	p	T081	C1709380
27802446	1575	1577	CI	T081	C0009667
27802446	1595	1610	HLA-B*50 allele	T028	C0002085
27802446	1615	1625	associated	T080	C0439849
27802446	1631	1641	conversion	T169	C0439836
27802446	1645	1664	generalized disease	T047	C0849867
27802446	1668	1676	patients	T101	C0030705
27802446	1682	1693	pure ocular	T047	C0751340
27802446	1694	1702	symptoms	T184	C1457887
27802446	1706	1719	disease onset	T079	C0277793
27802446	1780	1792	interactions	T045	C0596610
27802446	1805	1817	pathogenesis	T046	C0699748
27802446	1821	1823	MG	T047	C0026896
27802446	1828	1844	genetic heritage	T169	C0314603